232 related articles for article (PubMed ID: 36490241)
1. Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
Kanbayashi Y; Shimizu M; Ishizuka Y; Sawa S; Yabe K; Uchida M
PLoS One; 2022; 17(12):e0278823. PubMed ID: 36490241
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis.
Kanbayashi Y; Ishizuka Y; Shimizu M; Sawa S; Yabe K; Uchida M
Support Care Cancer; 2022 Jul; 30(7):5831-5836. PubMed ID: 35355120
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Obayashi K; Minato K
Ann Palliat Med; 2023 Jul; 12(4):697-707. PubMed ID: 37081703
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.
Kamiya T; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984494
[No Abstract] [Full Text] [Related]
5. Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis.
Kanbayashi Y; Amaya F; Ueno H; Tabuchi Y; Ishikawa T; Takayama K; Taguchi T
Pharmazie; 2021 Apr; 76(4):175-178. PubMed ID: 33849704
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age.
Wild J; Webster L; Yamada T; Hale M
Drugs Aging; 2020 Apr; 37(4):271-279. PubMed ID: 32086791
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.
Fujita Y; Imai H; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Koizuka S; Saito T; Obayashi K; Kaira K; Minato K
J Palliat Med; 2023 Apr; 26(4):548-553. PubMed ID: 36971576
[No Abstract] [Full Text] [Related]
8. A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.
Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Sandoh M; Takei S; Arai K; Nishiba H; Mogi J; Kaira K; Minato K
Thorac Cancer; 2022 Aug; 13(16):2301-2308. PubMed ID: 35790500
[TBL] [Abstract][Full Text] [Related]
9. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of naldemedine for the treatment of opioid-induced constipation.
Song X; Wang D; Qu X; Dong N; Teng S
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):121-128. PubMed ID: 30652502
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of naldemedine for the treatment of opioid-induced constipation: A meta-analysis.
Esmadi M; Ahmad D; Hewlett A
J Gastrointestin Liver Dis; 2019 Mar; 28(1):41-46. PubMed ID: 30851171
[TBL] [Abstract][Full Text] [Related]
12. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Candy B; Jones L; Vickerstaff V; Larkin PJ; Stone P
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006332. PubMed ID: 29869799
[TBL] [Abstract][Full Text] [Related]
13. [Survey of Prophylactic Administration of Naldemedine for Opioid-induced Constipation].
Ozawa Y; Haruki Y; Ohata M; Isono H; Takahashi M; Tate A; Ukita S; Hayashi S
Yakugaku Zasshi; 2023; 143(2):183-189. PubMed ID: 36724931
[TBL] [Abstract][Full Text] [Related]
14. Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.
Takagi Y; Osawa G; Kato Y; Ikezawa E; Kobayashi C; Aruga E
BMC Gastroenterol; 2020 Jan; 20(1):25. PubMed ID: 32005157
[TBL] [Abstract][Full Text] [Related]
15. Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: A nationwide retrospective cohort study in Japan.
Abe H; Sumitani M; Matsui H; Inoue R; Fushimi K; Uchida K; Yasunaga H
Pharmacotherapy; 2022 Mar; 42(3):241-249. PubMed ID: 34967450
[TBL] [Abstract][Full Text] [Related]
16. A Retrospective Observational Study of Factors Affecting the Efficacy of Concurrent Prescription of Naldemedine for Opioid-Induced Constipation Caused by Oxycodone Tablets.
Yamada M; Jimaru Y; Torii S; Mitsuba N; Takahashi K
Biol Pharm Bull; 2023; 46(12):1826-1831. PubMed ID: 38044102
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
[TBL] [Abstract][Full Text] [Related]
18. Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer.
Katakami N; Oda K; Tauchi K; Nakata K; Shinozaki K; Yokota T; Suzuki Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Jun; 35(17):1921-1928. PubMed ID: 28445097
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer.
Katakami N; Harada T; Murata T; Shinozaki K; Tsutsumi M; Yokota T; Arai M; Tada Y; Narabayashi M; Boku N
J Clin Oncol; 2017 Dec; 35(34):3859-3866. PubMed ID: 28968171
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
Takata K; Nakazawa M; Honda K; Hashimoto S
Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]